Noble Rock Acquisition Corp. (NASDAQ:NRAC) and Constellation Acquisition Corp. I (NYSE:CSTA) announced this morning that they have each announced changes to their upcoming extension votes.
Noble Rock is moving its vote from January 25 to 10 am ET January 27. It has also slightly decreased the contribution its sponsor intends to make to the trust in connection with the vote. This contribution was previously set to the lesser of $110,000 and $0.06 per share and will now be a range of the lesser of $100,000 or $0.055 per share.
A $0.055 per share contribution would equate to exactly $100,000 if about 1,818,181 shares were left unredeemed. That would be a 92.5% redemption scenario. Should redemptions be less, the pro rata contribution will be less than $0.55.
Noble Rock also indicated in a previous proxy that some Class B shareholders intended to convert their shares into Class A shares in connection with the vote, but will no longer do so.
Constellation I, for its part, announced in an 8-K that it intends to adjourn its special meeting to give it more time to engage with its investors. They were to consider a proposal to allow the SPAC to extend its January 29 transaction deadline to April 29 and allow for up to nine further in one-month extensions.
The record date for that vote will remain December 27 when the special meeting reopens at its to-be-determined new time.
Both SPACs initially IPO’d in early 2021 without overfunding their trusts and with units containing 1/3 warrants. But, neither has announced a transaction in the roughly two years they have been searching.
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...
At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...
AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...